Trial Profile
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Furmonertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allist Pharmaceuticals
- 30 Jan 2020 Results (n=130) from NCT02973763 (n=14) and NCT03127449(n=116), assessing clinically efficacy with an acceptable toxicity profile in advanced NSCLC patients (including those with CNS metastases) with EGFR T790M mutation, published in the Journal of Thoracic Oncology
- 02 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2020 Planned End Date changed from 30 Jun 2019 to 30 Aug 2020.